Last reviewed · How we verify
NCT06016075: IBM-Renal
Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques
NA trial testing Hyperpolarised MRI in Kidney Cancer in 30 participants. Currently enrolling.
31 August 2025
Quick facts
| Lead sponsor | University of Cambridge |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 1 January 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Hyperpolarised MRI
- Sodium MRI
- Deuterium metabolic imaging (DMI) MRI
Conditions studied
- Kidney Cancer — all drugs for Kidney Cancer →
Sponsor
University of Cambridge
Who can join
18 and older, any sex, with Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to develop techniques for non-invasive imaging of biology in participants with benign or malignant renal masses based on the novel scanning MRI techniques, including recently invented Hyperpolarised MRI, deuterium metabolic imaging and sodium MRI. This imaging study will: 1) acquire imaging data from human tissues following the injection of hyperpolarised 13C pyruvate and use 13C-MRI to monitor changes in the ratio of 13C-lactate to 13C-pyruvate; 2) acquire imaging data from human tissues using Sodium MRI or 3) acquire imaging data from human tissues following the oral consumable of deuterated glucose. Data acquired during this physiological study will be used to optimise future imaging protocols.In the UK and possibly in other countries, there are some patients with renal masses that are over treated or undergo unnecessary procedures such as surgery or biopsies, as they are thought to have a malignant tumour or a more aggressive tumour but after the procedure it is found that the mass was benign. The aim of this study is to determine whether one or all of these imaging techniques can differentiate between benign and malignant renal masses with the view to developing the techniques further and hopefully reducing the need for over treatment or unnecessary procedures in patients with benign masses.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multiarm, non-randomised, single-centre feasibility study-investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocol.
Horvat-Menih I, McLean MA, Zamora-Morales MJ, Wylot M, et al · · 2024 · cited 4× · PMID 39461869 · DOI 10.1136/bmjopen-2024-083980 -
Investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): a multi-arm, non-randomised feasibility study
Horvat-Menih I, McLean M, Zamora-Morales MJ, Wylot M, et al · · 2024 · DOI 10.1101/2024.05.03.24306816
Verify or expand the search:
- PubMed search for NCT06016075
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hyperpolarised MRI
Trials testing the same drug.
- NCT03687645 — Hyperpolarised 13C-Pyruvate MRI Study · NA · unknown
Other recruiting trials for Kidney Cancer
Currently open trials in the same condition.
- NCT07401875 — A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) · Phase 1 · recruiting
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
- NCT06964958 — 177LuPSMA in Renal Cell Carcinoma · Phase 2 · active not recruiting
Other University of Cambridge trials
Trials by the same sponsor.
- NCT07106216 — Evaluating Near-infrared Spectroscopy Devices for Monitoring Traumatic Brain Injury · not yet recruiting
- NCT07341230 — Deep Brain Stimulation to Understand and Treat Addiction · NA · recruiting
- NCT07154836 — Call for Life: Exploring mHealth Solutions for Enhancing Childhood Vaccinations Among Displaced Children in Conflict-aff · NA · enrolling by invitation
- NCT06844539 — taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs · NA · recruiting
- NCT07026656 — Pre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-assoc · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06016075 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cambridge
- Last refreshed: 5 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06016075.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing